Jade Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $844.33M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 6, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | During market hours | – | $-0.86 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | – | $-12.10 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 25, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | During market hours | – | – | – |
Press releases
Announcements Jade Biosciences filed with the SEC
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Jade Biosciences Announces Proposed Underwritten Public Offering
Other events · EX-99.1 to Form 8-K
Jade Biosciences Announces Pricing of Public Offering of Common Stock
Other events · EX-99.2 to Form 8-K
JADE101 Phase 1 Interim Data
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Jade Biosciences Announces $45 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
Report of Independent Registered Public Accounting Firm
Results of operations · Other events · EX-99.2 to Form 8-K
Jade Biosciences Announces $135 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Disclaimers Forward Looking Statements Certain statements in this
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.3 to Form 8-K
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Prepaid expenses and other current assets
Acquisition or disposition completed · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Managements Discussion and Analysis of Financial Condition and Results of Operations.
Acquisition or disposition completed · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
Acquisition or disposition completed · Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million
Material agreement · Acquisition or disposition completed · Results of operations · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Material agreement · Acquisition or disposition completed · Results of operations · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Disclaimers Forward Looking Statements Certain statements in this
Regulation FD disclosure · EX-99.1 to Form 8-K
Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals
Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aerovate Therapeutics Declares Special Cash
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Aerovate Therapeutics to Explore Strategic Alternatives
Other events · EX-99.1 to Form 8-K
Announces 24-Week Topline Results from the Phase 2b Portion of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aerovate Therapeutics Announces First Quarter
Results of operations · EX-99.1 to Form 8-K
Meaningfully Improving the Lives of
Regulation FD disclosure · EX-99.1 to Form 8-K
Aerovate Therapeutics Announces Full-Year 2023
Results of operations · EX-99.1 to Form 8-K
Meaningfully Improving the Lives of
Regulation FD disclosure · EX-99.1 to Form 8-K
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aerovate Therapeutics Announces Third Quarter
Results of operations · EX-99.1 to Form 8-K
Aerovate Therapeutics Announces Second Quarter
Results of operations · EX-99.1 to Form 8-K
Aerovate Therapeutics Announces First Quarter
Results of operations · EX-99.1 to Form 8-K
Aerovate Therapeutics Announces Full-Year 2022
Results of operations · EX-99.1 to Form 8-K
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K